Nuvalent, Inc.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domai…
Biotechnology
US, Cambridge [HQ]
Balance Sheet
5 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Assets | 3.00 | 10.00 | 293.00 | 482.00 | 732.00 | |
|
Current
|
3.00 | 10.00 | 290.00 | 477.00 | 726.00 | |
| Cash And Equivalents | 3.00 | 10.00 | 68.00 | 241.00 | 335.00 | |
| Assets | 3.00 | 10.00 | 293.00 | 482.00 | 732.00 | |
| Accounts Receivables (AR) | - - | - - | - - | - - | - - | |
| Inventory | - - | - - | - - | - - | - - | |
| Short Term Investments | - - | - - | 219.00 | 230.00 | 384.00 | |
| Other Current Assets | - - | - - | 2.00 | 5.00 | 6.00 | |
|
Non Current
|
- - | - - | 3.00 | 4.00 | 5.00 | |
| Property, Plant, Equipment (Net) | - - | - - | - - | - - | - - | |
|
Intangible Assets
|
- - | - - | - - | - - | - - | |
| Goodwill | - - | - - | - - | - - | - - | |
| Long Term Investments | - - | - - | - - | - - | - - | |
| Other Non Current Assets | - - | - - | 3.00 | 4.00 | 5.00 | |
| Liabilities | 20.00 | 41.00 | 8.00 | 19.00 | 31.00 | |
|
Current
|
4.00 | 4.00 | 8.00 | 19.00 | 31.00 | |
| Accounts Payable | - - | - - | 1.00 | 4.00 | 2.00 | |
| Short Term Debt | 3.00 | 1.00 | - - | - - | - - | |
| Deferred Revenue | -3.00 | -1.00 | - - | - - | - - | |
| Tax Payable | - - | - - | - - | - - | - - | |
| Other Current Liabilities | 3.00 | 3.00 | 5.00 | 12.00 | 22.00 | |
|
Non Current
|
16.00 | 37.00 | - - | 7.00 | - - | |
| Long Term Debt | 2.00 | 2.00 | - - | - - | - - | |
| Leasing Obligations | - - | - - | - - | - - | - - | |
| Deferred Non Current Tax Liabilities | - - | - - | - - | - - | - - | |
| Other Non Current Liabilities | 14.00 | 35.00 | - - | 7.00 | - - | |
| Equity | -17.00 | -31.00 | 285.00 | 462.00 | 700.00 | |
| Stockholders' Equity | -17.00 | -31.00 | 285.00 | 462.00 | 700.00 | |
| Retained Earnings | -17.00 | -31.00 | -78.00 | -160.00 | -286.00 | |
| Common Stock | - - | - - | - - | - - | - - | |
| Preferred Stock | 14.00 | 35.00 | 293.00 | - - | - - | |
| Profit | -11.00 | -14.00 | -46.00 | -73.00 | -126.00 | |
| Dividends | - - | - - | - - | - - | - - | |
| Minority Interest | - - | - - | - - | - - | - - | |
| Other Stockholders' Equity | - - | -34.00 | 69.00 | 623.00 | 986.00 | |
| Loss Other Compr. Income | -14.00 | - - | - - | - - | - - |